Clearbridge Health Limited Announces Lapse of Term Sheet for Proposed Acquisition of Elpis Biopharmaceuticals

Key Highlights for Investors

• Lapse of Acquisition Term Sheet: Clearbridge Health Limited (“the Company”) has announced that the binding term sheet for its proposed acquisition of Elpis Biopharmaceuticals Pte. Ltd. (“Elpis”) has lapsed as of the long stop date, 23 January 2026. This means the potential acquisition will not proceed under the current agreement.
• Background: The Company initially entered into the binding term sheet on 28 April 2025, with intentions to acquire Elpis Biopharmaceuticals. The document set out the preliminary terms for the proposed acquisition, subject to further definitive agreements and due diligence.
• Reason for Lapse: According to the Company, the term sheet lapsed automatically in accordance with its terms upon reaching the specified long stop date. No further force or effect will be attributed to the agreement.
• Impact on Financials: Management has stated that the lapse of the term sheet is not expected to have any material impact on the net tangible assets or earnings per share of Clearbridge Health Limited and its subsidiaries for the current financial year ending 31 December 2026.

Important Considerations for Shareholders

• Potential Price-Sensitive Information: While the termination of the term sheet for the proposed acquisition might have limited immediate financial impact, it could be perceived as a setback for the Company’s growth strategy. The market may interpret the failure to move forward with the acquisition as a missed opportunity for business expansion, potentially affecting investor sentiment and the Company’s share price.
• Strategic Direction: The Company has not provided specific reasons for the lapse beyond the expiry of the long stop date. Shareholders may wish to seek further clarification from management regarding the Company’s future plans for growth, acquisitions, or strategic partnerships, as this could influence future valuation.
• Regulatory and Sponsor Oversight: The announcement has been reviewed by the Company’s sponsor, UOB Kay Hian Private Limited, but has not been examined or approved by the Singapore Exchange Securities Trading Limited (SGX-ST). As such, the SGX-ST takes no responsibility for the contents of the announcement.
• Contact Information: For further information, shareholders may contact Mr Lance Tan, Senior Vice President at UOB Kay Hian Private Limited, at 83 Clemenceau Avenue, #10-01 UE Square, Singapore 239920, telephone (65) 6590 6881.

Summary

The lapse of the term sheet for the acquisition of Elpis Biopharmaceuticals marks a notable development in Clearbridge Health Limited’s M&A activities, signaling that the Company will not be pursuing this acquisition at this time. While the Company expects no material impact on its 2026 financials, investors should monitor for further updates regarding the Company’s strategic initiatives, as future moves in M&A could influence market confidence and share price performance.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a qualified financial advisor before making investment decisions. The Singapore Exchange Securities Trading Limited (“SGX-ST”) has not examined or approved the contents of this article and assumes no responsibility for its accuracy.

View Clearbridge Historical chart here